Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Chromatin accessibility of an enhancer that regulates the expression of a disease-associated microRNA is affected in monocytes from patients with systemic lupus erythematosus, highlighting this enhancer as a potential therapeutic target.
New research shows that a recombinant antibody that binds type II collagen protects against the development of arthritis in mice by blocking neutrophil recruitment.
In an observational study, SARS-CoV-2 antibody therapy used as pre-exposure prophylaxis reduced the incidence of COVID-19 in individuals with rheumatic diseases.
New research shows that the FGF10–FGFR1 axis is highly activated in lining fibroblast-like synoviocytes during relapsing rheumatoid arthritis and is a potential therapeutic target.
New research shows that deficiency of the sulfation-related SLC26A2 affects osteocyte formation, and that targeting downstream mediators can ameliorate SLC26A2-deficient osteoporosis.
A monoclonal antibody targeting a peptide that replicates the proinflammatory properties of IL-17 has shown potent activity and an acceptable profile of adverse effects in pre-clinical studies.
New findings suggest that liposome-mediated delivery of a specific microRNA inhibitor can restore anti-inflammatory macrophage polarization and reduce joint inflammation in mice.
Although inflammatory arthritis induced by immune-checkpoint inhibitors clinically resembles that of rheumatoid arthritis or psoriatic arthritis, research shows that it differs in its associated T cell response.
Nanoparticles consisting of long DNA molecules in association with Ca2+ and PPi4− ions can modulate the pathological osteoporotic microenvironment and promote bone repair.
New research provides insights into the mechanisms underlying the renal protective effects of sodium glucose cotransporter 2 inhibitors in lupus nephritis.
An antibody that targets CD19 on B cells has shown greater inhibitory efficacy than that of anti-CD20 B cell depletion therapy in animal models of autoimmune diseases.
New research indicates that extracellular aminoacyl-tRNA synthetases contribute to the pathogenesis of rheumatoid arthritis by functioning as alarmins, and could be a novel therapeutic target.
Researchers have developed ‘urchin-like’ ceria nanoparticles with inherent antioxidant properties that efficiently carry therapeutic microRNA, enabling gene therapy following intra-articular injection in a mouse model of osteoarthritis.
Platelet activity and the formation of monocyte–platelet aggregates contribute to the production of IL-1β and the development of cardiovascular lesions in Kawasaki disease.
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
New findings suggest that interosseous tendon inflammation is already present in individuals with clinically suspect arthralgia and is linked to an increased risk of developing clinical arthritis.
A new report indicates that low back pain remains the leading cause of disability worldwide, and that case numbers are expected to increase substantially in the coming decades.
New findings implicate TAp63 as a potential target of methotrexate in T cells, providing insight in the mechanism of action of this drug, including its suppressive effects on regulatory T cells.
